Evidence map›Paper›PMID 40034037›Full record

ReviewFuture medicinal chemistry2025

Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception.

Jeanine Giarolla, Kelsey A Holdaway, Maryam Nazari, Laila Aiad, Bidisha Sarkar, Gunda I Georg

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeanine GiarollaDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Kelsey A HoldawayDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.ORCID 0009-0004-5277-9500
Maryam NazariDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Laila AiadDepartment of Chemistry, University of Minnesota, Minneapolis, MN, USA.
Bidisha SarkarDepartment of Chemistry, University of Minnesota, Minneapolis, MN, USA.
Gunda I GeorgMedicinal Chemistry, University of Minnesota Twin Cities, Minneapolis, MN, USA.ORCID 0000-0002-8900-9460

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Allosteric CDK2 inhibitor Discovery and Development for Male ContraceptionR61HD099743 · NICHD · UNIVERSITY OF MINNESOTA · PI CHENNATHUKUZHI, VARGHEESE MANI, GEORG, GUNDA I. · 2019 to 2020
$780k
DEL Screening Campaign for Contraceptive and Cancer TargetsR21HD115181 · NICHD · UNIVERSITY OF MINNESOTA · PI GEORG, GUNDA I. · 2024 to 2025
$426k
NCI NIH HHS P50 CA116201NICHD NIH HHS 1R21 HD115181NICHD NIH HHS R21 HD115181NICHD NIH HHS R61 HD099743
6 · The paper itself

Abstract

The review discusses progress in discovering cyclin-dependent kinase 2 (CDK2) inhibitors for cancer treatment and their potential for male contraception. It summarizes first-, second-, and third-generation CDK inhibitors and selective CDK2 inhibitors currently in clinical trials for cancer. Novel strategies to discover allosteric inhibitors, covalent inhibitors, and degraders are also discussed.

Indexed as

Antineoplastic AgentsCell Cycle ProteinsCyclin-Dependent Kinase 2CyclinsNeoplasmsProtein Kinase InhibitorsAnimalsHumansMaleAntineoplastic AgentsCDK2 protein, humanCell Cycle ProteinsCyclin-Dependent Kinase 2CyclinsProtein Kinase InhibitorsCDK2 inhibitorsclinical trialscovalent bindersdegradersmale contraceptionOncological therapeuticsorthosteric and allostericSpy1

Identifiers

PMID40034037
PMCPMC11901406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.